|
LEUKEMIA : HAIRY CELL
|
||||||
|
Regimen/Number Of Patients |
Drug Dose and Route |
Leukopenia/ Neutropenia Toxicity |
Anemia Toxicity |
Other Grade III-IV Toxicities |
Emetogenic Potential |
Consequences of Adverse Event(s) |
|
Cladribine (Saven A, et al. Blood. 1998;92:1918-26)
N= 358
|
Cladribine 0.1 mg/kg/d IV continuous Infusion days 1 – 7 Administer one cycle |
Neutropenia Grade III * 16% Grade IV* 71%
In first 135 consecutive patients treated
|
Grade III 20% Grade IV 2% |
Neutropenic Fever * 42% Documented Infections * 13% Thrombocytopenia 20%
*Grade unknown
|
Days 1-5 – Level 1 |
Infection mortality 1% Viral reactivation 2.5% of patients (5 herpes simplex, 3 herpes zoster, 1 CMV retinitis )
|
|
Interferon alfa 2b (Golomb HM, et al. J Clin Oncol. 1986;4: 900-05)
N= 64
|
Interferon alfa 2b MU/m2 SQ TIW (escalation to 10 MU/m2 for non-responders)
|
|
|
Flu- like Symptoms (Grade III) 195 Skin Disorders (Grade III) 2% injection-Site Reaction (Grade III) 3% Central and Peripheral Nervous System (Grade III) 2%
|
Level 1 |
|